Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Tivic Health Systems ( (TIVC) ).
On June 18, 2025, Tivic Health Systems, Inc. and Statera Biopharma, Inc. entered into an Amended and Restated Exclusive License Agreement, which supersedes their previous agreement from February 11, 2025. The new agreement allows Tivic to pay royalties in cash or securities and requires payments up to $5.6 million to be made directly to Avenue Capital on behalf of Statera, indicating strategic financial adjustments in their collaboration.
Spark’s Take on TIVC Stock
According to Spark, TipRanks’ AI Analyst, TIVC is a Neutral.
The overall stock score of 43 reflects Tivic Health Systems’ current financial difficulties, including declining revenues and negative profitability. However, recent strategic initiatives and corporate events provide some optimism for future growth. The stock’s technical indicators and valuation remain weak, necessitating significant improvements in financial performance and market sentiment to enhance stock attractiveness.
To see Spark’s full report on TIVC stock, click here.
More about Tivic Health Systems
Tivic Health Systems, Inc. operates in the healthcare industry, focusing on developing and commercializing proprietary products that address unmet needs in the medical field. The company is involved in acquiring exclusive licenses for innovative health solutions.
Average Trading Volume: 1,274,169
Technical Sentiment Signal: Sell
Current Market Cap: $3.74M
See more data about TIVC stock on TipRanks’ Stock Analysis page.